The FDA has delayed safety reviews of the abortion drug mifepristone for 26 years and recently argued in court that pro-life states like Louisiana lack standing to sue over its chemical abortion regulations. Louisiana is challenging the FDA's 2021 decision to allow mifepristone to be mailed, which weakened safety protocols and has led to illegal abortions in pro-life states, but the FDA and the drug manufacturer argue that Louisiana must first petition the FDA and that such petitions would not necessarily fail, despite past delays and lack of response from the agency.
Read →Loading search…